---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-086685"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:31:40.922766+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Palvella posts updated corporate presentation; no material new disclosures

## Summary
- Filed an 8-K under Item 7.01 furnishing a corporate presentation dated September 2025.
- Presentation describes first-in-disease therapies for rare genetic skin diseases.
- No financial results, pipeline updates, or guidance changes disclosed in the filing.
- Presentation will be used in investor meetings going forward.

## SEC filing metadata
- accession: 0001104659-25-086685
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000110465925086685/0001104659-25-086685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000110465925086685/tm2525080d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-086685
- JSON: https://secwatch.observer/filing/0001104659-25-086685.json
- Plain text: https://secwatch.observer/filing/0001104659-25-086685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.